Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience.

Karan RajaNicole DanielSusan MorrisonRuben PatelJessica GergesKomal NadeemBrandon ChenSoo KangMitesh PatelDonald BeggsMark AttallaNaveen BallemMona Philips

Published in: Journal of pharmacy practice (2021)

Tocilizumab did not appear to influence clinical outcomes in our study population, irrespective of timing of administration. Adverse events were not considered drug-related.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
coronavirus disease
sars cov
rheumatoid arthritis patients
case report
systemic lupus erythematosus